<DOC>
	<DOCNO>NCT01882920</DOCNO>
	<brief_summary>The aim study ass whether cytoreductive surgery ( CRS ) hyperthermic intraperitoneal chemotherapy ( HIPEC ) use protocol intravenous fluid therapy combine goal direct fluid therapy ( GDT ) associate significant change morbidity , length hospital stay mortality compare standard fluid therapy . Patients undergo CRS hipec randomly divide two treatment group . The GDT group receive fluid intravenous therapy accord specific treatment protocol guide monitored hemodynamic parameter assess use arterial pressure signal monitoring assess stroke volume cardiac output via automate pulse contour analysis ( Flotrac/VigileoÂ® ) ; control group receive standard fluid therapy ( crystalloid colloid ) . Fluid therapy regimen free control group target GDT group . In group , investigator evaluate incidence major abdominal systemic complication , total duration hospital stay , mortality , total amount fluid administer , breakdown ( crystalloid/colloid ) total number colloid bolus administer .</brief_summary>
	<brief_title>Goal Directed Therapy ( GDT ) Cytoreductive Surgery ( CRS ) Hyperthermic Intra Peritoneal Chemotherapy ( Hipec )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Patients select Cytoreductive surgery hyperthermic intraperitoneal chemotherapy Patients age 18 , patient hemodynamically significant aortic regurgitation heart rhythm disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cytoreductive surgery</keyword>
	<keyword>hyperthermic intraperitoneal chemotherapy</keyword>
	<keyword>Goal direct fluid therapy</keyword>
</DOC>